Genomictree Valuation

Is A228760 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A228760 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A228760 (₩15220) is trading below our estimate of fair value (₩54002.72)

Significantly Below Fair Value: A228760 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A228760?

Key metric: As A228760 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A228760. This is calculated by dividing A228760's market cap by their current book value.
What is A228760's PB Ratio?
PB Ratio	2.8x
Book	₩128.62b
Market Cap	₩365.01b

A228760 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	131.5x
Enterprise Value/EBITDA	-20.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A228760's PB Ratio compare to its peers?

The above table shows the PB ratio for A228760 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	7.8x
A199800 ToolGen	15.6x	n/a	₩310.2b
A084650 LabGenomics	0.9x	n/a	₩207.9b
A347850 D&D Pharmatech	4.8x	n/a	₩361.6b
A174900 AbClon	9.7x	n/a	₩259.6b
A228760 Genomictree	2.8x	107.8%	₩365.0b

Price-To-Book vs Peers: A228760 is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (7.8x).

Price to Book Ratio vs Industry

How does A228760's PB Ratio compare vs other companies in the KR Biotechs Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
A377740 BioNote	0.3x	n/a	US$344.40m
A950210 Prestige BioPharma	0.4x	n/a	US$138.51m
A109960 AP Healthcare	0.3x	n/a	US$68.18m
A950220 NeoImmuneTech	0.4x	n/a	US$17.18m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A228760 is expensive based on its Price-To-Book Ratio (2.8x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A228760's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A228760 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A228760's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%